Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + Prednisolone
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Function of Renal Transplant
Conditions
Function of Renal Transplant
Trial Timeline
Nov 1, 2010 → Oct 1, 2022
NCT ID
NCT01095172About Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + Prednisolone
Rituximab + Tacrolimus + Mycophenylate mofetil + Hydrocortisone + Prednisolone + Prednisolone is a approved stage product being developed by Astellas Pharma for Function of Renal Transplant. The current trial status is unknown. This product is registered under clinical trial identifier NCT01095172. Target conditions include Function of Renal Transplant.
What happened to similar drugs?
20 of 20 similar drugs in Function of Renal Transplant were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01095172 | Approved | UNKNOWN |
Competing Products
20 competing products in Function of Renal Transplant